ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HUM vs CI // EV/EBITDA & P/E VALUATION

Humana Inc. (NYSE) VS. The Cigna Group (NYSE) • 15-METRIC TALLY: HUM 3 — CI 10
▲ EV/EBITDA & P/E VALUATION LEADER: CI
valuation
18.4x
valuation
6.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HUM VS. CI) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HUM CI SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 21.80% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 8.30% 8.80% -0.50 CI /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 18.4x 6.1x +12.30 CI /valuation <GO>
Free Cash Flow Yield 0.75% -3.51% +4.26 HUM /fcf-yield <GO>
Operating Margin 2.10% 3.30% -1.20 CI /operating-margins <GO>
Net Profit Margin 0.90% 2.20% -1.30 CI /net-margins <GO>
Revenue Growth (YoY) 10.10% 11.20% -1.10 CI /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.86% 2.04% -1.18 CI /dividend-safety <GO>
Altman Z-Score & Debt/Equity 5.03 2.70 +2.33 HUM /balance-sheet <GO>
Piotroski F-Score Quality 7/9 5/9 +2.00 HUM /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 53.9 55.8 -1.90 CI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.88 1.12 -0.24 CI /macro-sensitivity <GO>
Forward P/E Multiple 39.2x 12.3x +26.90 CI /forward-pe <GO>
Enterprise Scale & Market Cap $50.14B $78.85B -$28.71B CI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HUM REV CI REV HUM GROSS % CI GROSS % HUM FCF CI FCF
FY 2025 $129.66B $274.90B — 21.8% $375.0M -$2.77B
FY 2024 $117.76B $247.12B — 26.1% $2.39B -$757.4M
FY 2023 $106.37B $195.26B — — -$805.8M $3.03B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HUM // BETA 0.88
CI // BETA 1.12